These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 34330208)

  • 1. Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy.
    Scuteri D; Corasaniti MT; Tonin P; Nicotera P; Bagetta G
    J Headache Pain; 2021 Jul; 22(1):87. PubMed ID: 34330208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.
    Hou M; Xing H; Cai Y; Li B; Wang X; Li P; Hu X; Chen J
    J Headache Pain; 2017 Dec; 18(1):42. PubMed ID: 28389966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin Gene-Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis.
    Chan TLH; Cowan RP; Woldeamanuel YW
    Headache; 2020 Jul; 60(7):1489-1499. PubMed ID: 32515018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.
    Scuteri D; Tonin P; Nicotera P; Vulnera M; Altieri GC; Tarsitano A; Bagetta G; Corasaniti MT
    Toxins (Basel); 2022 Aug; 14(8):. PubMed ID: 36006191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis.
    Fernández-Bravo-Rodrigo J; Pascual-Morena C; Flor-García A; Saz-Lara A; Sequí-Dominguez I; Álvarez-Bueno C; Barreda-Hernández D; Cavero-Redondo I
    Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
    Hong P; Wu X; Liu Y
    Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developments in targeting calcitonin gene-related peptide.
    Alabbad S; Figueredo N; Yuan H; Silberstein S
    Expert Rev Neurother; 2024 May; 24(5):477-485. PubMed ID: 38557226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review.
    Jiang Y; Huang ZL
    Medicine (Baltimore); 2022 Jun; 101(24):e29361. PubMed ID: 35713436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
    Chen ST; Wu JW
    Prog Brain Res; 2020; 255():123-142. PubMed ID: 33008504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
    Tringali G; Navarra P
    Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis.
    Soni P; Chawla E
    Clin Neurol Neurosurg; 2021 Oct; 209():106893. PubMed ID: 34464833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.
    Robblee J; Hakim SM; Reynolds JM; Monteith TS; Zhang N; Barad M
    Headache; 2024 May; 64(5):547-572. PubMed ID: 38634515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.
    Bigal ME; Walter S
    CNS Drugs; 2014 May; 28(5):389-99. PubMed ID: 24638916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine.
    Cho S; Kim BK
    Curr Pain Headache Rep; 2024 Aug; 28(8):743-751. PubMed ID: 38683278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants.
    Do TP; Al-Saoudi A; Ashina M
    Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis.
    Lampl C; MaassenVanDenBrink A; Deligianni CI; Gil-Gouveia R; Jassal T; Sanchez-Del-Rio M; Reuter U; Uluduz D; Versijpt J; Zeraatkar D; Sacco S
    J Headache Pain; 2023 May; 24(1):56. PubMed ID: 37208596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
    Giri S; Tronvik E; Linde M; Pedersen SA; Hagen K
    Cephalalgia; 2023 Apr; 43(4):3331024231156922. PubMed ID: 36856015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.